Advertisement Pharmaceutical Business review - Page 3705 of 5281 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 15, 2026

Innovent licenses IBI355 rights to Spero for up to $1.1bn

Innovent Biologics has agreed an exclusive licence deal worth up to $1.1bn with Spero Therapeutics, granting Spero the rights to develop, research, manufacture and commercialise IBI355, also known as SP001, outside Greater China.

Continue
IBI355 targets CD40L, an immune signal protein involved in multiple immune pathways and immune-mediated diseases. Credit: THICHA SATAPITANON / Shutterstock.com.
July 15, 2026

FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN

pMN is a chronic autoimmune disease that can result in kidney damage and may progress to kidney failure. Credit: sasirin pamai / Shutterstock.com.
July 14, 2026

Novartis and Chai Discovery collaborate on antibody identification

Chai Discovery’s technology uses AI to predict molecular interactions and redesign biomolecules with targeted properties. Credit: Gorodenkoff / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Cellares and Sonoma partner to automate cell therapy manufacturing
  2. Takeda and Indonesia partner on plasma-derived therapies
  3. FDA approves MSD’s Keytruda combinations for MIBC
  4. Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
  5. Apertura and NIH institutes to test gene therapy for NPC1

PRESS RELEASES

SCHOTT Pharma Expands Ready-to-Use Portfolio with Sterile 1.5ml Cartridge
SCHOTT Pharma Expands Ready-to-Use Portfolio with Sterile 1.5ml Cartridge
Dr Imre Molnár Awarded With an Exceptional Scientific Honour – Tswett-Nernst European Award
Dr Imre Molnár Awarded With an Exceptional Scientific Honour – Tswett-Nernst European Award
HPLC 2025 in Bruges: Sharing Advanced Modelling Methods
HPLC 2025 in Bruges: Sharing Advanced Modelling Methods
Dr Imre Molnár Met Professor Ugur Sahin in Berlin, Laureate of the German National Prize, Together With His Wife Professor Özlem Türeci
Dr Imre Molnár Met Professor Ugur Sahin in Berlin, Laureate of the German National Prize, Together With His Wife Professor Özlem Türeci
Dr Imre Molnár Honoured With Tswett-Nernst European Award
Dr Imre Molnár Honoured With Tswett-Nernst European Award

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography